PURPOSE: Previously, polymer-attached zanamivir had been found to inhibit influenza A viruses in vitro far better than did small-molecule zanamivir (1) itself. The aim of this study was to identify in vitro-using the plaque reduction assay-a highly potent 1-polymer conjugate, and subsequently test its antiviral efficacy in vivo. METHODS: By examining the structure-activity relationship of 1-polymer conjugates in the plaque assay, we have determined that the most potent inhibitor against several representative influenza virus strains has a neutral high-molecular-weight backbone and a short alkyl linker. We have examined this optimal polymeric inhibitor for efficacy and immunogenicity in the mouse and ferret models of infection. RESULTS: 1 attached to poly-L-glutamine is an effective therapeutic for established influenza infection in ferrets, reducing viral titers up to 30-fold for 6 days. There is also up to a 190-fold reduction in viral load when the drug is used as a combined prophylactic/therapeutic in mice. Additionally, we see no evidence that the drug conjugate stimulates an immune response in mice upon repeat administration. CONCLUSIONS: 1 attached to a neutral high-molecular-weight backbone through a short alkyl linker drastically reduced both in vitro and in vivo titers compared to those observed with 1 itself. Thus, further development of this polymeric zanamivir for the mitigation of influenza infection seems warranted.
PURPOSE: Previously, polymer-attached zanamivir had been found to inhibit influenza A viruses in vitro far better than did small-molecule zanamivir (1) itself. The aim of this study was to identify in vitro-using the plaque reduction assay-a highly potent 1-polymer conjugate, and subsequently test its antiviral efficacy in vivo. METHODS: By examining the structure-activity relationship of 1-polymer conjugates in the plaque assay, we have determined that the most potent inhibitor against several representative influenza virus strains has a neutral high-molecular-weight backbone and a short alkyl linker. We have examined this optimal polymeric inhibitor for efficacy and immunogenicity in the mouse and ferret models of infection. RESULTS: 1 attached to poly-L-glutamine is an effective therapeutic for established influenza infection in ferrets, reducing viral titers up to 30-fold for 6 days. There is also up to a 190-fold reduction in viral load when the drug is used as a combined prophylactic/therapeutic in mice. Additionally, we see no evidence that the drug conjugate stimulates an immune response in mice upon repeat administration. CONCLUSIONS: 1 attached to a neutral high-molecular-weight backbone through a short alkyl linker drastically reduced both in vitro and in vivo titers compared to those observed with 1 itself. Thus, further development of this polymeric zanamivir for the mitigation of influenza infection seems warranted.
Authors: Jonathan Dushoff; Joshua B Plotkin; Cecile Viboud; David J D Earn; Lone Simonsen Journal: Am J Epidemiol Date: 2005-11-30 Impact factor: 4.897
Authors: Jayanta Haldar; Luis Alvarez de Cienfuegos; Terrence M Tumpey; Larisa V Gubareva; Jianzhu Chen; Alexander M Klibanov Journal: Pharm Res Date: 2009-12-15 Impact factor: 4.200
Authors: Jianghong An; Davy C W Lee; Anna H Y Law; Cindy L H Yang; Leo L M Poon; Allan S Y Lau; Steven J M Jones Journal: J Med Chem Date: 2009-05-14 Impact factor: 7.446
Authors: Mila Brum Ortigoza; Oliver Dibben; Jad Maamary; Luis Martinez-Gil; Victor H Leyva-Grado; Pablo Abreu; Juan Ayllon; Peter Palese; Megan L Shaw Journal: PLoS Pathog Date: 2012-04-26 Impact factor: 6.823
Authors: C Joaquin Caceres; Brittany Seibert; Flavio Cargnin Faccin; Stivalis Cardenas-Garcia; Daniela S Rajao; Daniel R Perez Journal: FEBS Open Bio Date: 2022-04-27 Impact factor: 2.792